Physician profile
Brian Valle
NPI 1992016497
$6,654.59
in general payments reported to CMS, 2019-2025
32 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $502 · 2021: $553 · 2022: $732 · 2023: $996 · 2024: $1,643 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,994.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,767.10 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $593.88 | 2019-2024 | Xarelto |
| Medtronic, INC. | $545.25 | 2022-2025 | Onyx Frontier, Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $537.16 | 2019-2025 | Lifevest |
| Heartflow, INC. | $365.07 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $284.38 | 2023-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $251.28 | 2023-2025 | |
| Atricure, INC. | $239.39 | 2022-2023 | |
| Abbott Laboratories | $233.25 | 2025 | Aveir |
| Lexicon Pharmaceuticals, INC. | $222.08 | 2023-2024 | Inpefa |
| Amgen INC. | $213.86 | 2023-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $203.94 | 2019-2024 | Farxiga, Brilinta |
| Angiodynamics, INC. | $131.43 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $110.64 | 2021-2022 | |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $106.03 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $104.94 | 2021-2025 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $97.29 | 2022-2025 | |
| Novo Nordisk INC | $96.50 | 2021-2025 | Wegovy, Ozempic |
| Philips North America LLC | $82.58 | 2023-2024 | (Ck4) Mcot |
| Kestra Medical Technology Services, INC. | $78.42 | 2024-2025 | Assure Wcd |
| E.R. Squibb & Sons, L.L.C. | $58.83 | 2023-2025 | Eliquis, Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $57.34 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $45.45 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $41.63 | 2019 | |
| Medtronic Vascular, INC. | $39.83 | 2019 | |
| Edwards Lifesciences Corporation | $33.11 | 2024 | |
| Ge Healthcare | $30.32 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $22.67 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.67 | 2023 | |
| Impulse Dynamics (USA) INC. | $18.97 | 2023 | Optimizer |
| Esperion Therapeutics, INC. | $14.55 | 2024 | Nexletol |
| Cardiovascular Systems INC. | $7.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Valle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.